Selank headaches: what the research shows

A recurring observation in online peptide communities is that Selank, the synthetic heptapeptide analogue of tuftsin developed at the Institute of Molecular Genetics in Moscow, sometimes produces headache and nausea in the first days of use. One thread on r/Peptides, posted in July 2025, describes a persistent 24/7 headache with nausea after starting Selank alongside BPC-157^[1]. The poster wondered whether norepinephrine was involved. The question is reasonable, because Selank does modulate catecholamine activity in the brain. The literature offers a partial answer, with several important caveats about the state of the evidence.

What Selank does to monoamine levels

A 2008 animal study in Experimental and Clinical Pharmacology (PMID 19093364) compared Selank's effects on brain monoamines across two mouse strains. At a dose of 0.3 mg/kg, Selank increased norepinephrine levels in the hypothalamus in both strains^[2]. Effects on serotonin and dopamine metabolites were strain-dependent and moved in opposite directions between the two groups. The authors concluded that Selank's anxiolytic effects are selective and vary with the baseline neurochemical state of the subject. Neither strain showed a consistent pattern that would cleanly predict one adverse effect type.

A 2008 study by Kozlovskiy and colleagues (PMID 18488898) explored a related question: what happens when the noradrenergic system is deliberately damaged in rats, and can Selank compensate? The researchers induced norepinephrine dysfunction through disulfiram, 6-OHDA, and hypoxic-hypercapnic stress, then measured memory and learning outcomes. Selank partly restored the impaired functions, suggesting the peptide can interact with the noradrenergic system when it is under stress. The study does not speak directly to what an intact noradrenergic system does when Selank is administered.

The enkephalin pathway and autonomic effects

The best-characterised mechanism for Selank is the inhibition of enkephalin-degrading enzymes. A 2001 study (PMID 11550013) showed Selank inhibits plasma enkephalinase with an IC50 of 15 micromolar, more potently than the reference peptidase inhibitors bacitracin and puromycin^[3]. By slowing the breakdown of enkephalins, Selank prolongs their availability in circulation. Enkephalins interact with opioid receptors and also with sympathetic tone. In theory, a peptide that acutely shifts enkephalin levels could produce transient autonomic changes, including changes in vascular tone that manifest as headache.

The same 2001 study noted that patients with generalised anxiety disorder had reduced tau(1/2) values for leu-enkephalin before treatment, correlated with autonomic symptom severity. Selank treatment increased these values. The connection between enkephalin half-life, sympathetic activity, and headache is not a direct line of evidence from any single trial, but it is a plausible pharmacological chain.

What the clinical trials report on tolerability

Two clinical studies published in Russian journals have directly compared Selank against benzodiazepines in patients with anxiety disorders. Medvedev and colleagues (PMID 25176261) studied 60 patients with phobic-anxiety and somatoform disorders and found that Selank had pronounced anxiolytic effects with a mild nootropic profile^[4]. A follow-up study (PMID 26356395) compared phenazepam monotherapy against combined phenazepam plus Selank in 70 patients and found that Selank reduced several unwanted phenazepam effects, including sedation, asthenia, and orthostatic symptoms. Neither published abstract reported headache as a distinct adverse event category. The full Russian-language texts may contain more granular tolerability data, but those data are not available in translation.

The 2008 trial by Zozulia and colleagues (PMID 18454096) compared Selank against medazepam in 62 patients with generalised anxiety disorder and neurasthenia. The abstract states that Selank produced anxiolytic effects similar to medazepam while also providing psychostimulant and anti-fatigue effects. Tolerability adverse events are not enumerated. Across all three trials the enrolled populations had anxiety disorders; the pharmacological context differs from self-reported use in healthy individuals seeking nootropic effects.

GABAergic activity and the dose question

Gene-expression studies published in Frontiers in Pharmacology (PMID 26924987, 2016; PMID 28293190, 2017) showed that Selank alters the expression of GABA receptor subunit genes in rat frontal cortex and in human neuroblastoma cells, pointing to GABAergic modulation as a second major mechanism alongside enkephalinase inhibition^[5]. A 2018 study comparing intraperitoneal versus intranasal routes (PMID 29787664) found that intraperitoneal Selank increases GABA receptor binding in the frontal cortex by 38%, while intranasal Selank increases NMDA receptor density by 23%, without changing GABA binding. The route of administration changes which receptors are primarily engaged. Community users overwhelmingly report intranasal use. If NMDA receptor upregulation is the dominant effect of intranasal Selank, the neurochemical picture differs substantially from the intraperitoneal studies that inform most of the clinical framing.

What we do not yet know

The published literature on Selank's adverse effects in humans is thin. The available clinical trials are small (30 to 62 patients per group), conducted in populations with diagnosed anxiety disorders, and published primarily in Russian-language journals without full English-language data on tolerability. There is no controlled, peer-reviewed study examining headache or nausea as outcomes in healthy subjects using intranasal Selank at the doses commonly reported in community forums. The question of whether elevated hypothalamic norepinephrine from Selank directly causes vascular headache in humans is not answerable from the current published record. For context on where the peptide sits in other jurisdictions, see the Selank regulation page and the broader peptide research library.

If you are experiencing persistent headaches after starting Selank, or any other peptide, the practical step is to stop use and consult a healthcare provider. Attributing the symptom to a specific neurotransmitter mechanism on the basis of current evidence would go further than the published record supports.